E

Edwards Lifesciences

Develops transcatheter heart valves and devices

Group Product Manager - US Marketing

Full-Time
$145k - $205k/yr+ Performance-based incentives
Expert
Bachelor's, Master's
Irvine, CA, USA
In PersonOn-site role at the corporate headquarters in Irvine, California.
Growth & MarketingProduct Marketing

About the job

Requirements
  • A bachelor's degree in a related field and at least 10 years of related marketing or healthcare industry experience, or equivalent work experience based on Edwards criteria.
  • A master's degree in a related field and at least 8 years of related marketing or healthcare industry experience, or equivalent work experience based on Edwards criteria.
Responsibilities
  • Develop and execute an annual product marketing plan, including marketing-related activities for Edwards products targeting physicians, hospital staff, sales representatives, and clinical specialists.
  • Develop and lead comprehensive marketing plans, including strategies and tactics for multiple major product launches, programs, and initiatives.
  • Build relationships with key opinion leaders to inform product launch plans and understand the current market environment and competition.
  • Develop marketing messages based on regional strategies, current literature, the competitive environment, and regulatory and legal requirements.
  • Develop product materials and programs supporting product launch and commercialization strategies.
  • Lead major projects for the Congress Management process.
  • Drive marketing collateral and labeling through legal and regulatory approval processes in collaboration with cross-functional stakeholders.
  • Lead product launch and program execution with regional partners, including Salesforce readiness and training on products, messaging, and competition.
  • Define and build clinical and economic evidence supporting the regional value proposition.
  • Lead digital marketing for account-based targeted outreach and broader awareness.
  • Manage budgets related to product lines, campaigns, and projects.
  • Analyze clinical and market data to assess the regional impact of potential product launches.
  • Lead significant process or corporate initiatives that impact and add value to the marketing organization.
Desired Qualifications
  • Marketing experience in the life sciences industry, preferably medical devices.
  • Experience directly engaging sales representatives, clinical specialists, and physicians, preferably interventional cardiologists.
  • Experience leading cross-functional teams on a product launch.
  • Experience working in life sciences sales.
  • Digital marketing experience.
  • Account-based marketing experience, including tailored messaging to customers.
  • Successful project management skills.
  • Expertise in Microsoft Office Suite.
  • Documentation, communication, interpersonal relationship, negotiation, and relationship management skills with the ability to drive achievement of objectives.
  • Extensive understanding of market research design and experience developing market research programs with an understanding of the commercial goals behind research.
  • Ability to forecast product lines for short- and long-term accuracy based on market development, sales trends, competition, and changing market dynamics.
  • Ability to assess and understand market share, pricing, average selling prices, and competitive dynamics.
  • Strong clinical knowledge and experience in the clinical areas where Edwards products are used or intended to be used, including understanding purchasing processes and product-adoption challenges in complex healthcare networks.
  • Ability to interact professionally with all organizational levels and proactively escalate issues to appropriate levels of management.
  • Ability to manage competing priorities in a fast-paced environment.

About the company

Edwards Lifesciences focuses on cardiovascular medical technologies, especially transcatheter heart valves. Its products enable repairing or replacing diseased heart valves through minimally invasive procedures rather than open-heart surgery. The company builds on a long history that began with the Starr-Edwards valve and now centers on valve therapies and related diagnostics to treat heart disease. It differentiates itself by specializing in valve technologies and transcatheter approaches, backed by a track record of clinical leadership and global reach. The goal is to improve patient outcomes by providing safer, less invasive valve treatment options for people around the world.

Company Size

10,001+

Company Stage

IPO

Headquarters

Irvine, California

Founded

1958

Get referred to Edwards Lifesciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CMS finalized expanded TAVR coverage September 10, 2026, enlarging addressable Medicare volume.
  • Q2 2026 sales rose 13.6% to $1.74 billion; management raised full-year guidance.
  • AUTUS approval and ECLIPTIS launch broaden growth beyond mature TAVR programs.

What critics are saying

  • FTC settled July 2026 JC Medical charges for $10 million and compliance oversight.
  • January 2026 injunction blocked JenaValve buyout, crippling Edwards' aortic-regurgitation acquisition strategy.
  • AtriaCure, Medtronic, and Boston Scientific attack Edwards' adjacencies; failure here destroys diversification.

What makes Edwards Lifesciences unique

  • Edwards owns SAPIEN TAVR leadership and the 2025 asymptomatic-label exclusivity.
  • AUTUS, approved October 1, 2026, creates a pediatric pulmonary-valve franchise.
  • ECLIPTIS, cleared July 2026, extends Edwards into surgical stroke-prevention during cardiac surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

10%

2 year growth

10%
WZUU
Oct 15th, 2026
FDA flags Edwards heart-valve delivery system issue after death, injury.

FDA flags Edwards heart-valve delivery system issue after death, injury. By Thomson Reuters Oct 15, 2026 | 6:38 PM Oct 15 (Reuters) - The US FDA on Thursday warned of a potentially high-risk issue involving certain Edwards Lifesciences delivery systems used in transcatheter mitral valve replacement after one death and one serious injury. The FDA said Edwards Lifesciences had asked customers to remove affected products from use and return them after receiving three reports of balloons bursting during inflation. The company reported one death and one serious injury associated with the issue as of October 5. The affected devices are certain Commander M delivery systems used with Edwards' SAPIEN M3 transcatheter mitral valve replacement system, which received US approval in December 2025. The FDA said balloon bursts could block blood vessels or prevent retrieval of the device, potentially requiring additional procedures, including surgery, in patients generally considered unsuitable for surgery. (Reporting by Sahil Pandey in Bengaluru; Editing by Anil D'Silva)

Business Insider
Oct 2nd, 2026
Edwards Lifesciences (EW) receives a Buy from RBC Capital.

Edwards Lifesciences (EW) receives a Buy from RBC Capital. Oct. 2, 2026, 09:46 PM RBC Capital analyst Kendall Au maintained a Buy rating on Edwards Lifesciences on October 1 and set a price target of $110.00. The company's shares closed yesterday at $85.19. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. According to TipRanks, Au has an average return of -3.6% and a 22.22% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edwards Lifesciences with a $103.40 average price target, representing a 21.38% upside. In a report released on September 28, Leerink Partners also reiterated a Buy rating on the stock with a $101.00 price target. Based on Edwards Lifesciences' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.74 billion and a net profit of $241.9 million. In comparison, last year the company earned a revenue of $1.53 billion and had a net profit of $329.8 million Based on the recent corporate insider activity of 110 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in August 2026, Annette Bruls, the CVP, EMEACLA of EW sold 2,644.00 shares for a total of $237,907.12. Read More on EW:

Business Wire
Oct 1st, 2026
Edwards Lifesciences wins FDA approval for AUTUS, first surgical pulmonary valve for pediatric patients

Edwards Lifesciences has received FDA approval for the AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed specifically for paediatric patients with congenital heart disease. The valve can be expanded as a child grows through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. The approval was based on a pivotal study that met its primary safety and effectiveness endpoints. All patients were free from device-related complications through 30 days, with no valve reinterventions through six months. Patients who completed one-year follow-up showed consistent outcomes with favourable valve performance. The AUTUS valve previously received FDA Breakthrough Device designation for addressing an important unmet need in paediatric cardiac care.

Yahoo Finance
Sep 8th, 2026
Edwards Lifesciences beats Q2 expectations, raises 2026 guidance despite lagging Dow by 5.7%

Edwards Lifesciences, an Irvine, California-based cardiovascular products company, has underperformed the Dow Jones Industrial Average in recent months. The stock is down 6.6% from its 52-week high of $96.29 reached on 7 July. Over the past three months, Edwards Lifesciences shares grew 2.8%, lagging the Dow's 3.5% gain. The 52-week performance shows similar underperformance, with the stock up 11.4% compared to the Dow's 17.1% increase. Despite this, the company reported strong Q2 results on 23 July, with net sales rising 13.6% year-over-year to $1.7 billion. Adjusted earnings per share of $0.78 beat Wall Street estimates. The company raised its 2026 sales growth guidance to 10-11% from 9-11% previously. Analysts maintain a "strong buy" consensus rating, with a mean price target suggesting 13.5% upside potential.

BioPharma Watch
Sep 2nd, 2026
Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit.

Edwards Lifesciences to present at the Deutsche Bank Healthcare Summit. Key Takeaway: Edwards Lifesciences Corporation will present at the Deutsche Bank Healthcare Summit on September 16, 2026. CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. A live webcast of the presentation will be available on their investor relations website. Market sentiment analysis. Positive factors. * Edwards Lifesciences is actively engaging with investors. * Participation in a prominent healthcare summit highlights company visibility. * CEO and CFO are presenting, indicating strong leadership presence. IRVINE, Calif.-(BUSINESS WIRE)-Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl Frequently asked questions. When will Edwards Lifesciences present at the summit? Edwards Lifesciences will present on September 16, 2026. Who will represent Edwards Lifesciences at the summit? CEO Bernard Zovighian and CFO Doretta Mistras will represent the company. Is there a webcast available for the presentation? Yes, a live webcast will be available on their investor relations website.